IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals IOTA Pharmaceuticals

IOTA Pharmaceuticals Ltd is a Life Sciences company, based in Cambridge UK, applying state-of-the-art, industry-leading technologies to human drug discovery projects.

We are currently partners in two European projects (total value of €18.5m), which are developing specific approaches in Fragment-based Lead Discovery and Natural Product Screening to clinical disease.

Human glioblastoma is our current therapeutic focus. Among other efforts IOTA participates in the WINDOW Consortium in which we are the coordinators of a global glioblastoma research network and glioblastoma drug bank. You can find recent developments in glioblastoma research on our resource page.

Learn more about IOTA's involvment in the WINDOW Consortium here.